Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
about
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewIg-like domain 6 of VCAM-1 is a potential therapeutic target in TNFα-induced angiogenesisThe Bioactivity of D-/L-Isonucleoside- and 2'-Deoxyinosine-Incorporated Aptamer AS1411s Including DNA Replication/MicroRNA Expression.Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation.MicroRNA-processing Enzymes Are Essential for Survival and Function of Mature Retinal Pigmented Epithelial Cells in Mice.
P2860
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
@en
type
label
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
@en
prefLabel
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
@en
P2860
P50
P1476
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
@en
P2093
Mohammad Ali Faramarzi
Shekoufeh Nikfar
P2860
P304
P356
10.1517/14712598.2015.1057565
P407
P577
2015-06-16T00:00:00Z